Anebulo Pharmaceuticals

Anebulo Pharmaceuticals is a clinical-stage company focused on developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse disorder. Their lead product candidate, ANEB-001, is a competitive antagonist at the human cannabinoid receptor type 1 (CB1). ANEB-001 is designed to block and reverse the negative effects of acute cannabinoid intoxication (ACI). It has completed dosing in a Phase 2 clinical trial evaluating its utility in treating ACI. Anebulo Pharmaceuticals is seeking FDA approval for ANEB-001 as a potential treatment for unintentional cannabis poisoning in children, a growing area of concern.

Jobs: